Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63


Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting.

Sundling C, Martinez P, Soldemo M, Spångberg M, Bengtsson KL, Stertman L, Forsell MN, Karlsson Hedestam GB.

J Infect Dis. 2013 Feb 1;207(3):426-31. doi: 10.1093/infdis/jis696. Epub 2012 Nov 16.


Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.

Richmond JF, Mustafa F, Lu S, Santoro JC, Weng J, O'Connell M, Fenyö EM, Hurwitz JL, Montefiori DC, Robinson HL.

Virology. 1997 Apr 14;230(2):265-74.


Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

Buckner C, Gines LG, Saunders CJ, Vojtech L, Srivastava I, Gettie A, Bohm R, Blanchard J, Barnett SW, Safrit JT, Stamatatos L.

Virology. 2004 Mar 1;320(1):167-80. Erratum in: Virology. 2004 Jul 20;325(1):164.


CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.

Sundling C, Schön K, Mörner A, Forsell MN, Wyatt RT, Thorstensson R, Karlsson Hedestam GB, Lycke NY.

J Gen Virol. 2008 Dec;89(Pt 12):2954-64. doi: 10.1099/vir.0.2008/005470-0.


Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

AIDS Vaccine Evaluation Group 022 Protocol Team..

J Infect Dis. 2001 Feb 15;183(4):563-70. Epub 2001 Jan 18.


Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein.

Schwartz DH, Cosentino LM, Shirai A, Conover J, Daniel S, Klinman DM.

J Acquir Immune Defic Syndr. 1994 May;7(5):447-53.


Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL.

J Virol. 2008 Jan;82(2):638-51. Epub 2007 Oct 24.


Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL.

J Virol. 2005 Jan;79(2):771-9.


The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT.

Nat Rev Microbiol. 2008 Feb;6(2):143-55. doi: 10.1038/nrmicro1819. Review.


Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.

Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B, Rao SS, Loré K, Mascola JR, Wyatt RT, Douagi I, Karlsson Hedestam GB.

J Exp Med. 2010 Aug 30;207(9):2003-17. doi: 10.1084/jem.20100025. Epub 2010 Aug 2. Erratum in: J Exp Med. 2010 Sep 27;207(10):2283.


Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.

Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Markham P, Lu S.

Virology. 2006 May 10;348(2):341-53.


Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting.

McElrath MJ, Corey L, Berger D, Hoffman MC, Klucking S, Dragavon J, Peterson E, Greenberg PD.

J Infect Dis. 1994 Jan;169(1):41-7.


Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD.

Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1882-6.


Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.

Earl PL, Wyatt LS, Montefiori DC, Bilska M, Woodward R, Markham PD, Malley JD, Vogel TU, Allen TM, Watkins DI, Miller N, Moss B.

Virology. 2002 Mar 15;294(2):270-81.


Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.

Ye L, Sun Y, Lin J, Bu Z, Wu Q, Jiang S, Steinhauer DA, Compans RW, Yang C.

Virology. 2006 Aug 15;352(1):74-85. Epub 2006 May 24.


Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G.

J Infect Dis. 1998 Feb;177(2):301-9.


Adenovirus vectored vaccines.

Natuk RJ, Davis AR, Chanda PK, Lubeck MD, Chengalvala M, Murthy SC, Wade MS, Dheer SK, Bhat BM, Murthy KK, et al.

Dev Biol Stand. 1994;82:71-7.


Supplemental Content

Support Center